Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues of timely news and insightful strategies for reducing costs and improving outcomes, delivered by First Class U.S. Mail and electronically,
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest grouped for convenient reading
    • Bonus reports for subscribers, and
    • Regular postings from your editor.
View a sample and get more information
March 10, 2017

Recent Stories

From Drug Benefit News - The rising cost of insulin, which is placing the drug out of reach for some patients, is driven by factors that include innovative new therapies and the lack of a generic alternative, stakeholders say. But underneath lies a dispute between pharmaceutical manufacturers, PBMs and payers involving insulin list prices, rebates and the way in which drug prices are set — and those players blame each other for the problem. “The prices for drugs are set by one group: the drugmakers,” says Pharmaceutical Care Management Association (PCMA) President Mark Merritt. Read more

One health insurer continues to forge ahead with value-based arrangements in the… Read more

CMS is planning changes to the way it tracks opioid overuse and… Read more

As specialty drug costs continue to rise and show few signs of… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

March 22, 2017
Bonus Insight Reports for Subscribers

Several special reports covering key areas of concern to today’s health care executives are now available in your Subscriber Library. These original reports from the AIS Health editorial team are filled with business insights and practical advice on the pharmacy issues that affect payers and providers the most. Access them at

January 17, 2017
Long-Awaited Biosimilar Interchangeability Draft Guidance Is Out

FDA finally unveils interchangeability draft guidance for biosimilars, expects “that applications generally will include data from a switching study or studies in one or more appropriate conditions of use,” among other criteria

January 12, 2017
FDA Finalizes Naming Guidance for Biologics, Biosimilars

In final guidance, FDA says all biologics, not only biosimilars, will have four-letter suffixes; agency still considering “appropriate suffix format” for interchangeable biosimilars

It's quick and easy to sign up for FREE access to!

Why do I need to register?